A Genome-wide Survey of the Prevalence and Evolutionary Forces Acting on Human Nonsense SNPs  by Yngvadottir, Bryndis et al.
ARTICLE
A Genome-wide Survey of the Prevalence and Evolutionary
Forces Acting on Human Nonsense SNPs
Bryndis Yngvadottir,1 Yali Xue,1 Steve Searle,1 Sarah Hunt,1 Marcos Delgado,1 Jonathan Morrison,1,2
Pamela Whittaker,1 Panos Deloukas,1 and Chris Tyler-Smith1,*
Nonsense SNPs introduce premature termination codons into genes and can result in the absence of a gene product or in a truncated and
potentiallyharmful protein, so they are often considereddisadvantageous and are associatedwithdisease susceptibility. As such,wemight
expect thedisruptedallele tobe rare and, inhealthypeople, observedonly inaheterozygous state.However, some, like those in theCASP12
and ACTN3 genes, are known to be present at high frequencies and to occur often in a homozygous state and seem to have been advan-
tageous in recent human evolution. To evaluate the selective forces acting on nonsense SNPs as a class, we have carried out a large-scale
experimental survey of nonsense SNPs in the human genome by genotyping 805 of them (plus control synonymous SNPs) in 1,151
individuals from 56 worldwide populations. We identiﬁed 169 genes containing nonsense SNPs that were variable in our samples, of
which 99 were found with both copies inactivated in at least one individual. We found that the sampled humans differ on average by
24 genes (out of about 20,000) because of these nonsense SNPs alone. As might be expected, nonsense SNPs as a class were found to be
slightly disadvantageous over evolutionary timescales, but a few nevertheless showed signs of being possibly advantageous, as indicated
by unusually high levels of population differentiation, long haplotypes, and/or high frequencies of derived alleles. This study underlines
the extent of variation in gene content within humans and emphasizes the importance of understanding this type of variation.Introduction
The theory that gene duplication is a major factor in
shaping evolution was proposed many years ago by Sus-
umu Ohno1 and is now widely accepted. The idea that
gene loss can also contribute signiﬁcantly to evolution is,
however, a newer one and was proposed by Maynard
Olson.2 Common sense may lead us to consider gene loss
as a bad thing and to associate adaptation with genes
that are somehow ‘‘better.’’ However, as the thrifty gene
theory3 proposed, some genes that were advantageous in
the past may have become a burden in modern times.
One molecular mechanism for gene loss is the introduc-
tion of a premature termination codon (PTC). This can
result from a nonsense mutation, a frame-shifting indel
or a splice-site mutation with the skipping of a single
exon containing a number of nucleotides that cannot be
divided by three (reviewed in Cartegni et al.4). A PTC could
result in a shorter protein, but truncated proteins are likely
to be deleterious and are usually eliminated by a process
called nonsense-mediated mRNA decay (NMD).5,6 If the
NMD pathway is triggered, it will eliminate the production
of the protein, and the gene product will be completely
lost. However, if the PTC is located either in the last exon
or less than 50–55 nucleotides upstream of the last exon-
exon boundary, NMD can be evaded, resulting in the
production of a truncated protein.5,7
A gene-loss event begins with a mutation within a single
individual, and if the disrupted allele (hereafter referred to
as the ‘‘stopallele,’’ as opposed to thenondisrupted ‘‘normal
allele’’) is neutral, it can either increase or decrease its
frequency in a population by the random effects of genetic224 The American Journal of Human Genetics 84, 224–234, Februardrift.However, if the stopallele turns out tobeharmful to its
carrier, it will tend to be eliminated by the forces of negative
selection, whereas should it be advantageous, positive
selection will act to increase its frequency. Although
nonsense SNPs are common causes of genetic disease,8
the stop alleles in the CASP129 (MIM *608633) and
ACTN310 (MIMþ102574) genes are found at high frequen-
cies, areoften inahomozygous state, and seemtohavebeen
advantageous in recent human evolution. Carriers of the
stop allele in CASP12 are more resistant to severe sepsis11,
and the stop allele in ACTN3 has been associated with
increased endurance in athletic performance.12,13
Recent studies14,15 have provided us with important
insights into the number, location within the protein, and
predicted effects of nonsense SNPs in silico by using publicly
available data from the dbSNP database. We have now
extended these investigations to test the less-is-more
hypothesis2 by evaluating the evolutionary forces acting
on nonsense SNPs as a class, genotyping 805 such SNPs in
56worldwidepopulations, andresequencingagenecontain-
ing one example and its surrounding region. Our aimwas to
identify outliers that could potentially reveal additional
contributions of gene loss to the evolution of our species.
Material and Methods
DNA Samples
DNA samples were obtained from the HapMap and extended
HapMap populations16,17 and the human genome diversity cell
line panel (HGDP-CEPH),18 from which the H104819 subset was
used. The samples successfully genotyped were derived from
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(Figure S1 available online). The samples sequenced were 22 CEPH
Utah residents with ancestry from northern and western Europe
(CEU), 23 Yoruba in Ibadan, Nigeria (YRI), 23 Han Chinese in
Beijing (CHB), and 23 Luhya in Webuye, Kenya (LWK).16 In addi-
tion, one chimpanzee (Pan troglodytes) sample was included as an
outgroup. All HapMap samples were purchased from the Coriell
Institute for Medical Research (Camden, New Jersey, USA); the
HGDP-CEPH collection18 was kindly provided by Howard Cann
(CEPH, Paris, France), and the chimpanzee sample was purchased
from the ECACC (Salisbury, Wiltshire, UK).
Data Generation
Genotyping of 1,536 SNPs
Assay designs were attempted for all nonsense SNPs in dbSNP
build 121; assays that failed at the design stage and others that
passed the design but were known to fail from previous genotyp-
ing attempts were excluded, leaving 805 nonsense SNPs to be
tested. We analyzed only nonsense SNPs that introduce stop
codons (sometimes referred to as ‘‘stop gained’’) and excluded
SNPs causing a stop codon read-through (‘‘stop lost’’). Addition-
ally, 731 synonymous SNPs were added to provide a total of
1,536 SNPs, the number required for one bundle of an Illumina
BeadArray. The synonymous SNPs were chosen to act as controls:
although not perfectly neutral, they nevertheless provide an
approximation of neutral variants. We selected these synonymous
SNPs to roughly match the sources (submitters) of the nonsense
SNPs in order to match SNPs that might have been called on the
basis of poor sequencing or discovery in particular populations.
Many investigators have contributed to the discovery of the
SNPs in databases by sequencing a limited (and sometimes very
small) number of individuals; the sequenced regions were not
consistent throughout the genome and were generally not well
documented. Interpretation of the SNP genotypes in additional
individuals can thus potentially be inﬂuenced by the discovery
process, an effect known as ‘‘ascertainment bias.’’ We incorporated
a number of factors into our study design so that we could reach
useful conclusions, despite such bias. First, by starting from the
set of all SNPs in the database, we avoided the most extreme forms
of ascertainment bias, and below we show examples of nonsense
SNPs conﬁned to non-European samples and demonstrate that
an overtly Europe-centric bias has been avoided. Second, we
compared analyses of nonsense SNPs with source-matched anal-
yses of synonymous SNPs to ensure that the analyses were subject
to the same ascertainment bias. Third, we concentrated largely on
analyses less inﬂuenced by ascertainment bias.
Genotyping was carried out by the Sanger Genotyping Platform
Group via the Illumina GoldenGate assay20 with the primers listed
in Table S1, and the results were subjected to sequential quality-
control ﬁlters. Each plate contained three duplicates, and SNPs
with more than 33% discrepancies between duplicates were
excluded. The Gene Call (GC) score, which gives the conﬁdence
of the genotype read (intensity), was then estimated. A very low
value is not to be trusted. Genotypes without call, individual geno-
typeswith aGC score less than 0.25, assayswith amedianGC score
lower than 0.3, and assays with less than 80% data were also dis-
carded. Additional manual assessments were also applied. First,
we excluded nonsense SNPs that overlapped with Vega21 pseudo-
genes. We then excluded SNPs if the ancestral state could not be
inferred. Lastly, we used the Tblastx tool to search for the ORF of
the sequence surrounding SNPs that had ‘‘stop lost’’ listed as
a consequence and got rid of those for which the ancestral state
(chimpanzee) was found to be the PTC and the derived stateThe Americ(human) was found to be a read through of the protein. The ﬁnal
datasetweused in the analysis consistedof 453 SNPs (169nonsense
and 284 synonymous) that passed the quality controls and were
polymorphic in our samples. The genotype of each sample is
provided in Table S2 (a tab-delimited .txt ﬁle).
Resequencing MAGEE2
Two ~6.5 kb fragments that cover the whole MAGEE2 gene and
an additional ~5 kb on each side of it were ampliﬁed by long-
polymerase chain reaction (long-PCR). Primers are listed in Table
S1. Reactions (15 ml) contained 13High-Fidelity PCR Buffer (Invi-
trogen, Paisley, UK), 2 mMMgSO4, 200 mM each dNTP, 0.6 U Plat-
inum Taq DNA Polymerase High Fidelity (Invitrogen), 0.4 mM of
each primer and 125 ng genomic DNA. A touchdown protocol
beginning with 2 min denaturation at 94C, followed by 15 cycles
of 94C for 30 s, 68C for 30 s (temperature decreased by 0.5Ceach
cycle), and 68C for 6 min, then 20 cycles of 94C for 30 s, 58C for
30 s, and 68C for 6 min, and ﬁnishing with extension at 68C for
7 min was used. Nested PCR products of 500 (515%) bp overlap-
ping by 240 (530%) bp were then ampliﬁed with the primers in
Table S1; each 15 ml PCR contained 0.5 ml of 4003 diluted long-
PCR products, 0.5 U Platinum Taq (Invitrogen), 1 3 buffer
(Invitrogen), 1.6 mMMgCl2, 10 pmol of each primer, and 200 mM
of each dNTP, and the cycle conditions were 94C for 15 min,
30 cycles of 94C for 45 s, 61C for 45 s, 72C for 45 s, and ﬁnally
72C for 7 min. Products were sequenced on both strands by
the Sanger Large-Scale Sequencing Pipeline with BigDye Sanger
sequencing technology and a 3730 xl DNA Analyzer (Applied
Biosystems). Potential variable positions were ﬂagged by theMuta-
tion Surveyor v.2.0 software (SoftGenetics, PA, USA) and checked
manually. Four blind duplicates were included for quality control
and showed complete concordance. The SNP variation identiﬁed
inMAGEE2 is provided in Table S3 (a tab-delimited .txt ﬁle).
Data Analyses
Descriptive Statistics
We used the Table Browser on the UCSC Genome Browser website
to retrieve the ancestral allele for ~98% (445/453) of the SNPs
from the ‘‘snp126OrthoPanTro2RheMac2’’ table. The chimpanzee
(Pan troglodytes) sequence provided the primary ancestral state,
but we accepted sequences from other primates (Macaca mulatta
or Lagothrix lagotricha) when the chimpanzee sequence was not
available. The derived allele was then deﬁned as the other observed
humanallele.We then lookedmanually for the ancestral state of the
missing 2% (eight SNPs) by using FASTA sequences and the NCBI
Blastn algorithm to ﬁnd the best hit within a primate reference
sequence. We obtained the derived allele frequency by direct allele
countingandusedaKolmogorov-Smirnov test toevaluate thediffer-
ence between the distributions of nonsense and synonymous SNPs.
We found 112 genes bearing nonsense SNPs and coding for
a single transcript. The remaining 57 nonsense SNPs were found
in genes undergoing alternative splicing and were reported in
more than one transcript. For such SNPs we used the transcript
showing the largest truncation in subsequent calculations. We
estimated the proportion of protein truncation each SNP would
cause as the percentage of the ancestral ORF length (100 (SNP
protein position/protein length*100)). We used the SNP2NMD
database22 to assess whether our nonsense SNPs were likely to
trigger NMD according to the 50–55-nucleotide rule.5 Approxi-
mately 63% (107) of our nonsense SNPs were in SNP2NMD, and
for these we set the ‘‘NMD distance’’ (distance between a SNP
and the 30-most exon-exon junction) to be >50 nucleotides for
the NMD pathway to be triggered. For the remaining 62 (~37%)an Journal of Human Genetics 84, 224–234, February 13, 2009 225
SNPs missing from SNP2NMD, we extracted information on the
location of the nonsense SNP with respect to exon-intron bound-
aries from Ensembl (releases 37 and 43) and calculated the predic-
tion for NMD manually.
We performed a gene ontology (GO)23 term-enrichment anal-
ysis on 167 genes containing nonsense SNPswith the DAVID chart
analysis tool.24 All available GO terms were used, and all human
genes (implemented in DAVID) were deﬁned as the background.
p values were calculated with the EASE score, which is a modiﬁed
conservative adjustment of the one-tailed Fisher’s exact test25 and
is implemented in DAVID. Terms with values below 0.05 were
considered to be enriched.
Statistical Analyses
FST
26 was calculated with the R package HIERFSTAT27 via the
37 population division (Figure S1), and differences between the
distributions of nonsense and synonymous SNPs were assessed
with the Kolmogorov-Smirnov test. For comparison with empir-
ical data, we downloaded a set of 650 K publicly available SNPs
genotyped by Stanford University in the HGDP-CEPH populations
and calculated their FST values to ﬁnd out whether our SNPs were
signiﬁcant outliers (i.e., lying above the 95th or 99th percentiles).
Heterozygosity, the probability that any two randomly chosen
samples from a population are the same, was calculated for each
SNP according to Nei.28 To estimate the strength of selection, we
calculated the average selection coefﬁcient(s) for each nonsense
SNP in our set by using estimates for the number of coding nucle-
otides in the human genome (6.03 107), the average mutation
rate (2.53 108/nucleotide/generation29), and the fraction of
mutations that can create a PTC (~1/20), together with our esti-
mate for the average number of stop alleles per human diploid
genome (46). A selection coefﬁcient close to zero represents
neutrality, and the higher the value, the more deleterious the
mutation will be. The diploid genomic rate at which nonsense
SNPs arise is 7.53 102/individual/generation. On average,
a nonsense SNP persists for 46/(7.53 102)¼ 613 generations,
implying s ~0.0016.
In order to calculate the relative extended haplotype homozy-
gosity (REHH) statistic30, we used the phased HapMap data
(Build36), which included the majority (131 out of 169) of our
nonsense SNPs; we then deﬁned each nonsense SNP as a ‘‘core’’
and included 100 kb regions on each side. As controls, we chose
30 ENCODE random regions (~500 kb each), which we assumed
to be neutral; this was a conservative assumption because random
regions might have contained selected genes. The REHH test was
performed with Sweep, and REHH was calculated with the default
setting of a 0.04 marker breakdown from the core SNP. We used
DnaSP31 to calculate the summary statistics Tajima’s D,32 Fu and
Li’s D, D*, F, and F*,33 Fu’s FS
34 and Fay andWu’s H.35 We obtained
the null distribution from simulations run by using a custom
modiﬁcation of the ms program36 and incorporating the best-ﬁt
demographic model for each population,37 and thus departures
from neutrality take into account known demographic inﬂuences.
Haplotypes for the resequenced data were inferred with PHASE
2.1.38,39 Median-joining networks40 were constructed from the
inferred haplotypes with Network 4.5 and used for estimating
the time to the most recent common ancestor (TMRCA) of a spec-
iﬁed set of chromosomes, under the assumption of a time of
6.5 million years ago for the chimpanzee-human split. TMRCA
was also estimated with GENETREE.41 GENETREE employs a full
maximum-likelihoodmethod that is based on the standard coales-
cent42 and assumes an inﬁnite-sites mutational model. We esti-
mated theta to be 5.95 by using a model of three populations226 The American Journal of Human Genetics 84, 224–234, February(African [YRIþ LKW], European [CEU], and Asian [CHB]) and
performed 100,000 simulations (Ne¼ 15,700 with chimpanzee-
human split 6.5 million years ago). Finally, with this value of theta
and the populations connected by the migration rates suggested
by the best-ﬁt demographic model,37 we estimated the TMRCA
by using ten runs each of ten million simulations and chose the
run with the lowest standard deviation, as recommended.41
Results
After genotyping1,536 SNPs in1,151 individuals,we identi-
ﬁed167 genes containing169nonsense SNPs thatwere vari-
able inoursamples.A full list of thegenes isgiven inTableS4,
including a summary of all the results presented here. Two
genes, CDKL1 (MIM *603441) and FMO2 (MIM *603955),
were found with two nonsense SNPs each (CDKL1 with
rs11570829 and rs7148089; FMO2 with rs2020866 and
rs6661174) and might therefore be suspected to be pseudo-
genes. However, as part of our manual assessment we had
excluded all genes that overlappedwith theVega set of pseu-
dogenes21 and because these two genes are not annotated as
pseudogenes, they are included in the results.
Genotyping revealed that on average the individuals in
our samples carry ~14 stop/stop homozygous SNPs and
~18 stop/normal heterozygous SNPs in their genome,
a total of ~46 stop alleles per diploid genome or ~23 per
haploid genome. Furthermore, these individuals were
found to differ on average by 24 genes per diploid genome
because of nonsense SNPs. Because the polymorphic
nonsense SNPs analyzed here are only a fraction of the
nonsense SNPs reported in the human genome (Figure 1),
and because these in turn are only a fraction of all
nonsense SNPs (but also contain some false positive calls),
these estimates are lower bounds, and the actual average
difference is likely to be higher. However, because the
distribution of our nonsense SNPs appears random in the
human genome, they can be considered to represent
nonsense SNPs as a class in the following analyses.
The Consequences of Nonsense SNPs
Next, we wished to understand the effects these 169 non-
sense SNPs might be having on the gene product and the
carrier. At the molecular level, the stop allele could result
in a truncated protein or in the complete loss of the gene
product if NMD is triggered.We found that the truncations
were distributed evenly throughout the polypeptide length
(Figure 2). Forty-nine percent of the nonsense SNPs lead to
the deletion of>50%of the amino acid sequence, an exten-
sive truncation that might radically alter the protein struc-
ture and function. In addition, 55% of nonsense SNPs were
predicted to cause transcript degradation by NMD (in at
least one transcript), which would result in loss of the
gene function, and the rest of the nonsense SNPs (45%)
are expected to result in the production of a truncated
protein (Figure 2). Either way, most of these nonsense
SNPs could be having severe effects on the gene product.
Do these SNPs therefore potentially cause a recessive
disorder so that they are found only in the heterozygous13, 2009
Figure 1. Genome-wide Distribution of Nonsense SNPs on Chromosomes 1 to X in the Human Genome
The nonsense SNPs that were variable in our samples are displayed in red, and all nonsense SNPs reported in the human genome
(dbSNP127) are shown in blue.state in the HapMap and HGDP-CEPH donors? For 99
nonsense SNPs (59%), at least one stophomozygous sample
was found (Figure 3), showing that both copies of these
genes could be truncated in our sampled individuals. We
donotﬁndunexpectedlyhigh frequenciesofheterozygotes:The Americnosigniﬁcantdepartures fromHardy-Weinberg equilibrium
were found in individual populations. In addition, only
eight of the 169 nonsense SNPs were found in the Human
Gene Mutation Database (HGMD) of mutations associated
with human inherited disease.43 For three of these eightFigure 2. Even Distribution of Truncations
Truncations were calculated as the percentage of the ancestral ORF length. The 169 nonsense SNPs were sorted along the x axis according
to the amount of peptide truncation, starting at 1 for the lowest truncation and ending at 169 for the highest truncation. The identifying
number of the SNP displayed in the figure can be found in Table S4. Orange labels transcripts where NMD is predicted to be triggered with
the complete loss of the gene product, whereas green refers to transcripts where NMD is evaded because the nonsense SNP is located
either in the last exon or less than 50 nucleotides upstream of the last exon-exon boundary.an Journal of Human Genetics 84, 224–234, February 13, 2009 227
Figure 3. Frequencies of Stop Homozygotes, Normal Homozygotes, and Heterozygotes for Each Variable Nonsense SNP
The genotype frequencies of normal homozygotes (green), heterozygotes (purple), and stop homozygotes (orange) were plotted on a log-
arithmic scale. The nonsense SNPs were sorted along the x axis according to the frequency of stop homozygotes. The identifying number
can be found in Table S4.SNPs, we did not ﬁnd individuals homozygous for the stop
allele, but for theotherﬁveSNPswedid, and for twoSNPs (in
the NPPA (MIM *108780) and FMO2 genes), individuals
homozygous for the stop allele were found at a high
frequency. It therefore appears thatvery fewof thenonsense
SNPs represent low-frequency disease-causing alleles.
Gene-Ontology Enrichment Analysis
To further investigate the functional and physiological
consequences of these nonsense SNPs as a class, we used
GO information to determine whether there was enrich-
ment of anymolecular function or biological process terms
in these ‘‘lost’’ genes. The GO analysis revealed an excess of
genes involved in olfactory reception and the nervous
system (Table S5). The ﬁrst category was expected to show
up because previous studies have indicated that humans
have a reduced number of active olfactory receptor
genes.44,45 Indeed, a recent study on nonprocessed pseudo-
genes inactivated in the human lineage reported an over-
representation of genes involved in chemoreception (to
which olfactory receptors belong) and immune response.46
The latter, however, was not observed in our study. Finding
an overrepresentation of genes involved in the nervous
system was, however, unexpected because such genes
have generally been shown to be very conserved.47
Considering the disruptive effects of nonsense SNPs, is it
possible that the overrepresentation of certain GO cate-
gories largely reﬂects a higher number of paralogs for genes
containing nonsense SNPs? If this were true, it might result
from the paralogs’ serving as a ‘‘backup system’’ for the dis-
rupted genes and thus reducing the negative selection pres-
sure on them. We noted that 51% of the nonsense SNP
genes have at least one paralog, whereas in comparison228 The American Journal of Human Genetics 84, 224–234, Februaryonly 35% of all human genes in Ensembl (release 50) are
reported to have a paralog. This difference was found to
be moderately signiﬁcant (Fisher’s exact test, p < 0.05), so
it is possible that their function is ‘‘backedup’’ byduplicated
paralogs in the human genome. However, it has been
demonstrated previously, for example with the ACTN3
gene,12 that althougha closely relatedgene cancompensate
for the function of a lost gene, the gene loss can still have
signiﬁcant physiological consequences.
Selective Forces on Nonsense SNPs
Although the nonsense SNPs investigated here are not
overtly associated with disease, we wished to test whether
they were, as a class, nevertheless mildly deleterious.
Slightly deleterious alleles are subject to weak negative
selection and consequently are expected show a different
derived allele frequency (DAF) spectrum with an enrich-
ment of rare derived alleles, as shown in a comparison
between nonsynonymous and synonymous SNPs.48 We
therefore compared the DAF spectrum of the nonsense
SNPs with that of synonymous SNPs in the same samples
(Figure S2). The derived stop allele of nonsense SNPs was
indeed found to be generally rarer than the derived allele
of synonymous SNPs (Kolmogorov-Smirnov test, p <<
0.001). This suggests that, as expected, weak negative selec-
tion is actingon stopalleles as a class to removevariants that
are harmful over an evolutionary timescale. Indeed,we esti-
mated the selection coefﬁcient(s) to be ~0.0016 (see Mate-
rial and Methods section), indicating that the stop alleles
have on average only a slight decrease in ﬁtness when
they are compared to the normal alleles. This is lower
than the value of 0.025 estimated for nonsense SNPs by
Gorlov et al.49 but similar to a value in the range of 103,13, 2009
Table 1. Summary of Outlier Nonsense SNPs
Gene Symbol
(MIM ID) Gene Description SNP Chromosome
Position
(B36)
Percent
Truncated
NMD
candidate DAF FST
a Heterozygosityb
Outlier
Signal
APOL3
(MIM *607253)
apolipoprotein rs11089781 22 34886714 85.61 YES 0.022 0.258 0.043 FST
C1orf105 open reading
frame
rs7532205 1 170688829 91.38 YES 0.045 0.265 0.086 FST
CASP12
(MIM *608633)
caspase rs497116 11 104268327 63.66 YES 0.962 0.241 0.074 DAF, FST
CD36
(MIM *173510)
thrombospondin
receptor
rs3211938 7 80138385 31.29 YES 0.017 0.242 0.032 REHH, FST
FMO2
(MIM *603955)
flavin-containing
monooxygenase
rs6661174 1 169444714 11.78 YES 0.959 0.284 0.079 DAF, FST
HPS4
(MIM *606682)
Hermansky-Pudlak
syndrome
rs3747129 22 25192041 53.50 YES 0.202 0.097 0.323 REHH
KIAA0748 KIAA0748 rs1801876 12 53630291 3.80 NO 0.364 0.240 0.463 FST
c
LPL
(MIM *609708)
lipoprotein lipase rs328 8 19864004 0.42 NO 0.086 0.036 0.157 REHH
MAGEE2 melanoma antigen rs1343879 X 74921254 77.10 NO 0.311 0.540 0.429 FST
c
NPPA
(MIM *108780)
natriuretic peptide
precursor
rs5065 1 11828655 0.65 NO 0.848 0.145 0.259 DAF, REHH
OR1B1 olfactory receptor rs1476860 9 124431062 39.81 NO 0.397 0.211 0.479 FST
c
Q8N8G3_HUMAN rs4723884 7 39615800 68.38 NO 0.225 0.225 0.349 FST
REG4
(MIM *609846)
regenerating
islet-derived
rs1052972 1 120138308 8.80 NO 0.490 0.211 0.500 FST
c
SEMA4C
(MIM 604462)
semaphorin rs12471298 2 96890515 16.91 NO 0.043 0.469 0.082 FST
c
SIGLEC12 sialic acid binding
Ig-like lectin
rs16982743 19 56696715 95.13 YES 0.198 0.221 0.317 FST
ZAN
(MIM *602372)
zonadhesin rs2293766 7 100209294 33.04 YES 0.261 0.399 0.386 FST
c
Columns: the official gene symbol with the MIM ID (when available), gene description, SNP ID (rs number), chromosome, and position (in build 36), percent
of the peptide truncation, whether or not the SNPs are predicted to trigger NMD (YES or NO), derived allele frequency (DAF), FST, level of heterozygosity, and
outlier signal. The outlier signal is identified as: FST > 0.2, DAF > 0.8 (one example), and REHH above the 95
th percentile of the control distribution.
a Calculated according to Weir and Cockerham26 across the 37 populations.
b Calculated according to Nei.28
c FST value is significant because it is above the 99
th percentile of the empirical distribution.calculated against deleterious heterozygous SNPs segre-
gating in the human population.50 Because we are using
a subset of the total nonsense SNPs in the human genome
and the average number of nonsense SNPs is actually likely
to be higher, our estimate of 0.0016 is an upper limit.
In contrast to this general trend, a few nonsense SNPs dis-
played a high DAF, and these include SNPs in the CASP12,
FMO2, and NPPA genes, with DAFs at 0.962, 0.959, and
0.848, respectively (Table 1). An excess of very high-
frequency derived variants has previously been observed
in the normalized site-frequency spectrum and can poten-
tiallybeexplainedbyancestralmisspeciﬁcation.48Although
the ancestral state of theCASP12nonsense SNP iswell estab-
lished9,46, this potential confounding factor might be rele-
vant for other genes. Among the additional genes, FMO2
codes for the precursor of atrial natriuetic peptide, and the
nonsense-SNP-carrying form has been shown to be catalyt-
ically inactive.51 Previous studies have further revealed
that the derived stop allele in FMO2 is ﬁxed in European
and Asian populations, whereas the ancestral active allele
has been found in African Americans and Hispanics51–53;
such distributions were conﬁrmed and extended in ourThe Americdata (Tables S2 and S4). If carriers of the functional allele
are exposed to thioureas (which are present in a wide range
of industrial, household, andmedical products), they are at
increased risk of pulmonary toxicity.52 Because exposure to
these chemicals is now widespread, it is interesting to
consider whether they might also have been present in the
pre-industrial environment and whether the stop allele
might have reached its high frequency because of positive
selection for protection against toxicity. In addition, the
stop allele in NPPA has previously been reported at a high
frequency in humanpopulations andwas shown to be asso-
ciated with a decreased risk of stroke recurrence.54 Stroke is
a disease of old age andmight not itself have exerted strong
selective pressure in the past, but the association with
a phenotype raises the possibility that the allele might be
linked to other advantageous phenotypes as well and could
thus be susceptible to positive selection. These three exam-
ples showthatnonsenseSNPscanbeassociatedwithpheno-
types that are advantageous in some environments, and so
we next investigated whether a subset of the nonsense
SNPs might show the evolutionary signature of such an
advantage: positive selection.an Journal of Human Genetics 84, 224–234, February 13, 2009 229
Population Differentiation
Because geographically separated populations might be
subject to distinctive selective environments, selection
can increase population differentiation at the selected
locus. We used FST
26 as ameasure of population differentia-
tion and found that when samples were grouped into 37
populations (Figure S1B), most SNPs (both nonsense and
synonymous) had low FST values within the 0.00–0.19 bin
(Figure S3), as might be expected for human SNPs.17,55–57
On average, nonsense SNPs had signiﬁcantly lower FST
values than synonymous SNPs (Kolmogorov-Smirnov test,
p < < 0.001). This is in accordance with a recent study55
that showed an excess of low FST values for nonsynony-
mous SNPs compared to other classes, such as synonymous
SNPs. Furthermore, after allowing for ascertainment bias by
matching the FST values to the minor allele frequency
(MAF), the authors came to the conclusion that the low
values observed were a signal of purifying rather than
balancing selection because the excess represented an
excess of rare but not intermediate variants. To test for
this in our data, we plotted the FST values of nonsense
SNPs against theirMAFand foundno signiﬁcant correlation
between the two. However, we also found that themajority
of low FST values are in SNPs with low MAF. We therefore
suspect that the excess of low FST values observed for the
nonsense SNPs here is also the consequence of purifying
selection acting against mildly deleterious mutations.
In order to assess the signiﬁcance of the individual FST
values, we compared them to the empirical-frequency-
matched distribution of values in the HGDP-CEPH panel.
We found 13 nonsense SNPs with FST values above 0.2,
and six of these were above the HGDP-CEPH 99th percen-
tile (in MAGEE2, SEMA4C (MIM 604462), ZAN (MIM
*602372), KIAA0748, REG4 (MIM *609846), and ORIB1;
Table 1), when less than two would be expected by chance.
Genotyping errors can be a source of unusually high FST
values55 but are unlikely to be responsible here. We found
no overall correlation between FST and heterozygosity
(Figure S4), but note that several of the nonsense SNPs dis-
playing high FST values also show outlier behavior in terms
of heterozygosity (Table 1). The SNPs in SEMA4C and
FMO2 have high FST values but a low heterozygosity, which
could indicate a recent population-restricted selective
sweep. The SNPs in MAGEE2 and ZAN, on the other
hand, have high FST values as well as high levels of hetero-
zygosity, which could be a sign of balancing selection or an
older selective sweep. It is therefore possible that several of
these genes have experienced non-neutral evolution.
Extended Haplotypes
To gain further insight into the possible action of recent
natural selection, we applied the REHH test.30 We found
no evidence of unusually extended haplotypes in the
nonsense SNPs as a class, which further indicates (unsur-
prisingly) that the majority of these SNPs are not positively
selected. Outliers above the 95th percentile (Figure S5 and
Table 1) include NPPA (again), LPL (MIM *609708), which230 The American Journal of Human Genetics 84, 224–234, Februarencodes lipoprotein lipase andhasbeen implicated indisor-
ders of lipoprotein metabolism, CD36 (MIM *173510),
which is a thrombospondin receptor, and HPS4 (MIM
*606682),which encodes theHermansky-Pudlak syndrome
4 protein. A previous study observed a signiﬁcant excess of
long-range haplotypes among nonsynonymous SNPs with
high FST values.
55 However, only CD36 identiﬁed here was
also reported with a high FST value (FST¼ 0.24); the others
had values below 0.15. It should be noted that MAGEE2,
our highest FST outlier, was not included in the REHH anal-
ysis because it is located on the X chromosome and appro-
priate controls were not available.
MAGEE2: An Example of Advantageous Gene Loss?
Finally, we investigated the nonsense SNP in MAGEE2
further by resequencing the gene and its surrounding
regions and applying sequence-based tests to determine
whether the evolutionary history of the region was
compatible with neutrality. This SNP displayed the highest
FST value of all, resulting from the presence of the stop
allele (A) at very high frequency in Asian and South-Amer-
ican populations but its virtual absence from European and
African populations (Figure 4A). The geographical distribu-
tion suggests that the derived stop allele arose before the
entry of humans into the Americas ~15–20 KYA and
most likely before the exit from Africa ~50 KYA. The
nonsense SNP truncated the protein by ~77%, although
NMD was not predicted to be triggered (Table S4).
We resequenced the gene in 91 individuals from four
HapMap populations, CEU, YRI, CHB, and LWK16,17 and
one chimpanzee. Thirty-two chromosomes were found to
carry the stop allele: 1 YRI, 28 CHB, 1 CEU, and 2 LWK.
These proportions are similar to the worldwide geograph-
ical distribution shown in Figure 4A. A total of 43 SNPs
were detected in the MAGEE2 gene (Table S3); the haplo-
types carrying the stop allele were much less diverse than
the normal ones and had a nucleotide diversity (p)
of 0.83 104 compared with 3.73 104 (Table 2). This
led to a higher diversity in the African populations
(p¼ 4.33 104 in YRI and 4.73 104 in LWK) than in
the CEU (p¼ 2.93 104) and CHB (p¼ 1.63 104), but
this is in accordance withmost other comparisons of diver-
sity within and outside Africa.17,58,59 The lower diversity
observed for the truncated version is consistent with posi-
tive selection, and to explore this possibility further we
applied additional tests. Neutrality tests (Table 2), which
took into account the demography of each population,
revealed two signiﬁcant departures from neutral expecta-
tion. Fewer haplotypes were found in the whole sample
than expected, as measured by Fu’s Fs.
34 In addition, Fay
and Wu’s H revealed an excess of high-frequency derived
alleles in the CHB, the one sample where a signal would
be expected if positive selection had driven the nonsense
SNP to high frequency.
A median-joining network was constructed from the
inferred haplotypes (Figure 4B). As was seen in the geo-
graphical distribution of the nonsense SNP (Figure 4A),y 13, 2009
Figure 4. MAGEE2
(A) Geographical distribution of stop (orange) and normal (blue) alleles in MAGEE2. HapMap populations are displayed separately because
they do not all have precise geographic locations. Pie areas are proportional to sample sizes.
(B) Median-joining network of inferred MAGEE2 haplotypes. Circle areas are proportional to the haplotype frequency and are color coded
according to population: CEU in yellow, CHB in green, LWK in pink, and YRI in red. Lines represent mutational steps between them (one or
two steps, according to length). An arrow shows the location of a nonsense SNP (rs1343879).there is a clear east-west division for the haplotypes, reﬂect-
ing the presence or absence of the nonsense SNP. All haplo-
types carrying the inactive form cluster together (inside red
circle in Figure 4B) such that there is one high-frequency
haplotype with the other nonsense-allele haplotypes only
one or two steps away. This pattern helps to explain the
signiﬁcantly negative value of Fay and Wu’s H in the CHB
sample by illustrating the moderately high frequency of
a derivedhaplotype cluster speciﬁc to theCHB. TheTMRCA
was estimated at 695 31 KY (Network) or 415 6 KY
(GENETREE), consistent with what would be expected on
the basis of the geographical distribution.
Discussion
The analyses described here have identiﬁed the general
characteristics of the class of human nonsense SNPs and
have also pinpointed a small number of nonsense SNPsThe Americathat appeared to be exceptional. Previous studies14,15,46
have been largely restricted to in silico investigations but
have revealed an abundance of nonsense SNPs in the
human genome and the potential impact of gene loss on
the human lineage after the split from the chimpanzee46.
As a consequence of the accumulation of nonsense SNPs,
functions such as chemoreception and immune response
display species-speciﬁc features in humans. The current
investigation focused on mutations that are still segre-
gating in the human population and reveals that nonsense
SNPs are surprisingly prevalent in the general human pop-
ulation, in contrast to previous reports that such SNPs are
infrequent in the human genome.60 Although our esti-
mate is a lower bound, we found that the sampled individ-
uals differ, on average, by 24 genes, or more than 0.05% of
their gene number, because of these nonsense SNPs. Only
three out of the 169 conﬁrmed variable nonsense SNPs
showed the pattern expected in the healthy populationTable 2. Summary Statistics for MAGEE2
Sample Characteristics Allele-Frequency Distribution Tests Haplotype Test
Sample
Sample Size
(chromosomes)
Number of
Polymorphic
Sites
Nucleotide
Diversity
(p) (3 104) Tajima’s D
Fu
& Li’s D
Fu
& Li’s D*
Fu
& Li’s F
Fu
& Li’s F*
Fay &
Wu’s H Fu’s Fs
Worldwideb 111 43 4.2 1.24 2.20 2.28 2.16 2.23 0.42 27.03a
YRI 26 22 4.3 0.49 0.07 0.00 0.26 0.18 3.10 4.25
LWK 21 21 4.7 0.24 0.26 0.29 0.12 0.16 2.93 4.15
CEU 33 17 2.9 0.68 1.58 1.35 1.54 1.34 1.05 2.36
CHB 31 11 1.6 1.10 0.14 0.58 0.54 0.87 8.32a 3.54
Active (allb) 79 36 3.7
Inactive (allb) 32 8 0.9
Inactive (CHB) 28 7 0.8
a p < 0.01 (one-sided tests, simulated distribution from the best-fit model).
b All samples (YRI, LWK, CEU, and CHB).n Journal of Human Genetics 84, 224–234, February 13, 2009 231
for known recessive-disease-causing alleles; namely, this
pattern is being listed in the HGMD and being present
in our samples only as heterozygotes. The remaining
67 nonsense SNPs that were found only as heterozygotes
could represent novel recessive-disease alleles, or they
could simply represent variants found at low frequency
by chance.
Ninety-nine nonsense SNPs were found in our popula-
tion samples in the homozygous (or hemizygous) state.
The samples are from anonymous individuals with no
phenotype information beyond sex and ethnicity, but
the ethical considerations guiding the sampling required
the donors to be adults competent to provide informed
consent, and so it is likely that the donors were overtly
healthy at the time of sampling. Truncation or loss of these
99 genes is therefore compatible with normal adult life and
cannot be strongly disadvantageous. Conﬁrmation of this
expectation is found in the presence of 18 of the 169 non-
sense SNPs in the Venter genome61; all 18 of these were
present in the homozygous state in HapMap or HGDP-
CEPH individuals. Nevertheless, population-genetic tests
suggested that nonsense SNPs are generally mildly delete-
rious and subject to weak negative selection (s ~0.0016),
which is reﬂected in the fact that their frequencies and
levels of population differentiation are lower than those
of synonymous SNPs.
One additional factor to consider is whether a signiﬁcant
proportion of the genes harboring nonsense SNPsmight in
fact be pseudogenes already inactivated by regulatory,
missense, or other mutations. Known (Vega) pseudogenes
were excluded from our study, and the genes examined in
more detail showed evidence of an active form, so the
proportion of pseudogenes seems likely to be low.
Direct insights into the phenotypic consequences of
nonsense SNPs could potentially be obtained by future
detailed studies of individuals of known genotype and
phenotype, from the inclusion of these SNPs in association
surveys, or from model organisms. Indirect insights come
from the patterns of variation in the population; such
patterns point to possible advantages associated with the
loss of individual genes such as MAGEE2, NPPA, FMO2,
LPL, and HPS4.
We chose to resequence the MAGEE2 gene to provide
more detailed insight into its evolutionary history. This
gene displayed limited but signiﬁcant evidence for a depar-
ture from neutrality and thus for positive selection
favoring the truncated version in the CHB; it most likely
originated shortly before the expansion out of Africa but
had a selective advantage restricted to East Asia and the
Americas. The MAGEE2 gene is a melanoma-associated
antigen that belongs to a family of MAGE genes found
predominantly on the X chromosome. Several members
of the MAGE gene family (including MAGEE2) are
expressed in tumor cells but are silent in normal adult
tissues except in the male germ line, leading to an alterna-
tive name for these genes, cancer-testis genes. Because of
their speciﬁc expression on tumor cells, these antigens232 The American Journal of Human Genetics 84, 224–234, Februarare potential targets for cancer immunotherapy62,63, but
their normal function is completely unknown and merits
further investigation. Other genes of particular evolu-
tionary interest include SIGLEC12, a member of a family
of sialic acid-binding genes showing rapid evolutionary
change, including the deletion of SIGLEC13, in humans.64
To conclude,we see the set ofnonsense SNPsdocumented
here as being particularly signiﬁcant for three areas of
genetics and medicine. First, sequencing is starting to be
used to survey genes or genomes for disease-associated vari-
ants and to inform genetic-risk counseling, including
whole-genome resequencing for personalized medicine.61
Nonsense SNPs discovered in such studies would merit
particular attention, but at least the 99 found here in
the homozygous state are not associated with mendelian
disorders, have no overt inﬂuence on the phenotype, and
are compatiblewithhealthy life. Second, there areneverthe-
less some situations in which generally neutral differences
in gene content have medical consequences: for example,
in allogeneic hematopoietic stem cell transplantation,
a donor lacking a gene can mount an immune reaction
against the tissues of a recipient with that gene, leading to
graft-versus-host disease.65 Donors and recipients should
be screened for potential gene differences, including those
resulting from these nonsense SNPs. Third, a general treat-
ment for a wide variety of genetic disorders caused by
nonsense SNPs has been proposed: administration of the
drug PTC124, which promotes read-through of premature
but not normal termination codons.66 Such treatment
would, if effective, also promote the expression of endoge-
nous nontarget genes carrying nonsense SNPs, and the
consequences of this should be evaluated. We need to
understand the full extent of human genetic variation
in order to reap the full beneﬁts of present and future
medicine.
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